التهاب الفقار اللاصق مع الصدفية الشديدة — بعد فشل مثبط IL-17A

References

DOI: 10.1136/ard-2022-223296

• In patients with significant psoriasis, an IL-17i may be preferred.
• Following a first b/tsDMARD failure, switching to another bDMARD (TNFi or IL-17i) or a JAKi should be considered.
• Figure 3 summarises the criteria for continuation, namely that after at least 12 weeks of treatment, the disease activity has substantially decreased, as assessed by the ASDAS clinical important improvement, that is, improvement in ASDAS ≥1.1, together with the positive opinion from the rheumatologist to continue.